Jounce spikes nearly 80% on Gilead plan to buy remaining rights for GS-1811 Check out this evening's top movers from around Wall Street, compiled by The Fly.
HIGHER
- Jounce Therapeutics (JNCE) up 77.7% after announcing Gilead to buy remaining rights for GS-1811
- Kala Pharmaceuticals (KALA) up 49.7% after announcing FDA accepted application for KPI-012
- Minerva Surgical (UTRS) up 28.6% following $30M private placement of common stock
LOWER- Clene (CLNN) down 6.6% after announcing Phase 2 COVID study showed no clinical benefit
- Iveric bio (ISEE) down 1.7% after selling IC-100 and IC-200 rights to Opus Genetics
Symbols:
JNCE KALA UTRS CLNN ISEE Keywords: Fly Intel, Wall Street, Top Stories, Stocks
